PMID- 34141867
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210619
IS  - 2372-7705 (Print)
IS  - 2372-7705 (Electronic)
IS  - 2372-7705 (Linking)
VI  - 21
DP  - 2021 Jun 25
TI  - Association of IDH mutation and 1p19q co-deletion with tumor immune 
      microenvironment in lower-grade glioma.
PG  - 288-302
LID - 10.1016/j.omto.2021.04.010 [doi]
AB  - Although the successful clinical trials of immunotherapy show promising 
      strategies for many cancers, its application in glioma has lagged in comparison 
      with the progress seen in other cancers. Both isocitrate dehydrogenase (IDH) 
      mutations and 1p/19q codeletions are critical molecular alterations affecting 
      therapeutic response in lower-grade glioma (LGG). The systematic and 
      comprehensive characterization of the immunological phenotypes with different 
      molecular subtypes is key to improving our understanding and application of 
      immunotherapies in LGG. Here, we collected the RNA-sequencing, somatic mutation, 
      and clinical data from 1,052 patients from The Cancer Genome Atlas and Chinese 
      Glioma Genome Atlas and stratified patients into three genetic subgroups: IDH 
      mutations with 1p/19q codeletions (IDH mut-codel), IDH mutations without 1p/19q 
      codeletions (IDH mut-noncodel), and IDH wild-type. Our evaluations revealed that 
      IDH mutations and 1p/19q codeletions were associated with distinct immunological 
      tumor microenvironments in LGG. In addition, immune cell infiltration, the 
      expression of immune checkpoint and human leukocyte antigen (HLA) gene, and the 
      activity of immune signaling pathways shared gradual increase from IDH mut-codel 
      to IDH wild-type. We further constructed and validated an immune-related 
      prognostic signature that presented high value in predicting the overall survival 
      time in LGG. In conclusion, our study may provide valuable information for 
      immunotherapy strategies in LGG patients.
CI  - (c) 2021 The Authors.
FAU - Lin, Wanzun
AU  - Lin W
AD  - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan 
      University Cancer Hospital, Shanghai 201321, China.
AD  - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, 
      Shanghai 201321, China.
FAU - Qiu, Xianxin
AU  - Qiu X
AD  - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, 
      Shanghai 201321, China.
AD  - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, 
      China.
FAU - Sun, Pian
AU  - Sun P
AD  - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan 
      University Cancer Hospital, Shanghai 201321, China.
AD  - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, 
      Shanghai 201321, China.
FAU - Ye, Yuling
AU  - Ye Y
AD  - Department of Radiation Oncology, Fujian Cancer Hospital and Fujian Medical 
      University Cancer Hospital, Fuzhou 35005, China.
FAU - Huang, Qingting
AU  - Huang Q
AD  - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, 
      Shanghai 201321, China.
AD  - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, 
      China.
FAU - Kong, Lin
AU  - Kong L
AD  - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan 
      University Cancer Hospital, Shanghai 201321, China.
FAU - Lu, Jiade J
AU  - Lu JJ
AD  - Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan 
      University Cancer Hospital, Shanghai 201321, China.
AD  - Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, 
      Shanghai 201321, China.
LA  - eng
PT  - Journal Article
DEP - 20210429
PL  - United States
TA  - Mol Ther Oncolytics
JT  - Molecular therapy oncolytics
JID - 101666776
PMC - PMC8167204
OTO - NOTNLM
OT  - 1p/19q codeletions
OT  - IDH mutations
OT  - bioinformatics
OT  - lower-grade glioma
OT  - molecular subtypes
OT  - tumor immune microenvironment
COIS- The authors declare no competing interests.
EDAT- 2021/06/19 06:00
MHDA- 2021/06/19 06:01
PMCR- 2021/04/29
CRDT- 2021/06/18 06:50
PHST- 2021/01/17 00:00 [received]
PHST- 2021/04/24 00:00 [accepted]
PHST- 2021/06/18 06:50 [entrez]
PHST- 2021/06/19 06:00 [pubmed]
PHST- 2021/06/19 06:01 [medline]
PHST- 2021/04/29 00:00 [pmc-release]
AID - S2372-7705(21)00060-7 [pii]
AID - 10.1016/j.omto.2021.04.010 [doi]
PST - epublish
SO  - Mol Ther Oncolytics. 2021 Apr 29;21:288-302. doi: 10.1016/j.omto.2021.04.010. 
      eCollection 2021 Jun 25.